Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    LivaNova

    NASDAQ: LIVN · Real-Time Price · USD
    45.74
    -0.89 (-1.91%)
    At close: Jun 13, 2025, 3:59 PM
    45.76
    0.04%
    After-hours: Jun 13, 2025, 05:26 PM EDT
    -1.91%
    Bid 35.72
    Market Cap 2.49B
    Revenue (ttm) 1.28B
    Net Income (ttm) -222.15M
    EPS (ttm) -4.07
    PE Ratio (ttm) -11.24
    Forward PE 11.84
    Analyst Buy
    Ask 47.06
    Volume 327,217
    Avg. Volume (20D) 796,969
    Open 45.95
    Previous Close 46.63
    Day's Range 45.60 - 46.47
    52-Week Range 32.48 - 57.35
    Beta 0.91

    About LIVN

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol LIVN
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for LIVN stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Why Price Moved

    Why Price Moved is a one-sentence explanation of why a stock is moving higher or down. By removing noise and collecting signals from news, press releases and SEC filings, we can pinpoint the trigger for price movements.
    1 month ago
    +23.72%
    LivaNova shares are trading higher after the compa... Unlock content with Pro Subscription
    2 months ago
    +5.53%
    LivaNova shares are trading higher. Needham reiterated a Buy rating on the stock.
    news image

    1 week ago · businesswire.com

    CORE-VNS Study Further Validates Effectiveness of LivaNova's VNS Therapy on Severe Focal Seizures in Both Children and Adults with Drug-Resistant Epilepsy

    LONDON--(BUSINESS WIRE)-- #epilepsy--LivaNova PLC announced completion of the CORE-VNS study further validating effectiveness of VNS Therapy for severe focal seizures in children & adults.

    news image

    1 week ago · businesswire.com

    LivaNova Announces CORE-VNS 24-Month Data Show Adjunctive VNS Therapy is Associated with Substantial Reductions in Generalized Tonic-Clonic Seizures in People with Drug-Resistant Epilepsy

    LONDON--(BUSINESS WIRE)-- #epilepsy--LivaNova PLC announced CORE-VNS 24-month data show adjunctive VNS Therapy associated with substantial reduction in generalized tonic-clonic seizures.

    news image

    1 week ago · businesswire.com

    LivaNova Initiates Process with U.S. Centers for Medicare and Medicaid Services for Reconsideration of National Coverage for VNS Therapy for Treatment-Resistant Depression

    LONDON--(BUSINESS WIRE)-- #depression--LivaNova PLC announced it initiated the process with U.S. CMS to seek reconsideration of national Medicare coverage for VNS Therapy in depression.

    news image

    1 month ago · businesswire.com

    LivaNova to Present at the Jefferies Global Healthcare Conference

    LONDON--(BUSINESS WIRE)-- #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced Vladimir Makatsaria, Chief Executive Officer, will participate in a fireside c...

    news image

    1 month ago · seekingalpha.com

    LivaNova PLC (LIVN) Q1 2025 Earnings Call Transcript

    LivaNova PLC (NASDAQ:LIVN ) Q1 2025 Earnings Conference Call May 7, 2025 8:00 AM ET Company Participants Briana Gotlin – Vice President, Investor Relations Vladimir Makatsaria – Chief Executive Office...

    news image

    1 month ago · zacks.com

    LivaNova (LIVN) Q1 Earnings and Revenues Surpass Estimates

    LivaNova (LIVN) came out with quarterly earnings of $0.88 per share, beating the Zacks Consensus Estimate of $0.75 per share. This compares to earnings of $0.73 per share a year ago.

    news image

    1 month ago · businesswire.com

    LivaNova Reports First-Quarter 2025 Results; Updates 2025 Guidance

    LONDON--(BUSINESS WIRE)-- #cardiacsurgery--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the first quarter ended March 31, 2025 and updated full-...

    news image

    1 month ago · businesswire.com

    LivaNova Announces 12-month Data from OSPREY Clinical Study for Moderate to Severe Obstructive Sleep Apnea, Demonstrating Strong Response and Durability of Therapy

    LONDON--(BUSINESS WIRE)-- #livn--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced 12-month, top-line data from its OSPREY randomized controlled trial (RCT), ev...

    news image

    2 months ago · businesswire.com

    LivaNova to Announce First-Quarter 2025 Results

    LONDON--(BUSINESS WIRE)-- #cardiacsurgery--LivaNova PLC will host a conference call to discuss its first-quarter 2025 results on Wed., May 7, 2025, at 1 p.m. London time (8 a.m. Eastern Time).

    Add to Watchlist